Edition:
United Kingdom

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
20 Aug 2018
Change (% chg)

$0.05 (+3.73%)
Prev Close
$1.34
Open
$1.33
Day's High
$1.43
Day's Low
$1.30
Volume
19,190
Avg. Vol
25,023
52-wk High
$3.70
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Soligenix Q2 Loss Per Share $0.18
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Soligenix Inc ::SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.18.Q2 REVENUE $1.7 MILLION VERSUS $1.0 MILLION.  Full Article

Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Soligenix Inc ::SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE.SOLIGENIX INC - BIOMARKERS FOR RICIN TOXIN VACCINE TESTING BEEN SUCCESSFULLY IDENTIFIED, FACILITATING POTENTIAL APPROVAL UNDER FDA "ANIMAL RULE".SOLIGENIX INC - FURTHER EFFICACY STUDIES IN NHPS EVALUATING POTENTIAL DOSING REGIMENS ARE ANTICIPATED IN 2018.SOLIGENIX - RIVAX DEMONSTRATED REDUCED NUMBER OF VACCINATIONS MAY BE REQUIRED TO ESTABLISH PROTECTION, POTENTIALLY UTILIZING ONLY 2 DOSES INSTEAD OF 3.  Full Article

‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Soligenix Inc :‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing.  Full Article

‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - ‍ACT Capital Management LLLP::‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​.  Full Article

Soligenix reports Q3 loss per share $0.17
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Soligenix Inc :Soligenix announces recent accomplishments and third quarter 2017 financial results.Q3 loss per share $0.17.Q3 revenue $1.82 million versus $2.96 million.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning

* SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR RIVAX® FOR PREVENTION OF RICIN POISONING Source text for Eikon: Further company coverage: